STB-HO, a novel mica fine particle, inhibits the teratoma-forming ability of human embryonic stem cells after in vivo transplantation
Metrics: PDF 1021 views | HTML 1711 views | ?
Soon Won Choi1,2,*, Tae-Hoon Shin1,2,*, Md. Hafiz Uddin1,2, Ji-Hee Shin1,2, Tae-Wook Kang2,3, Byung-Chul Lee1,2, Hyung-Sik Kim1,2, Yoojin Seo1,2, Sulaiman Shams1,4, Yeon-Kwon Jung5 and Kyung-Sun Kang1,2
1 Adult Stem Cell Research Center, College of Veterinary Medicine, Seoul National University, Seoul, Republic of Korea
2 Research Institute for Veterinary Science, College of Veterinary Medicine, Seoul National University, Seoul, Republic of Korea
3 Institute for Stem Cell and Regenerative Medicine in Kangstem Biotech, Biomedical Science Building, College of Veterinary Medicine, Seoul National University, Seoul, Republic of Korea
4 Stem Cells Regenerative Medicine Lab, Department of Biochemistry, Abdul Wali Khan University, Khyber Pakhtunkhwa, Pakistan
5 Seobong BioBesstech Co., Ltd., Yeoksam-dong, Kangnam-gu, Seoul, Republic of Korea
* These authors have contributed equally to this work
Kyung-Sun Kang, email:
Keywords: STB-HO, mica fine particle, teratoma formation, pluripotent stem cell, apoptosis
Received: June 16, 2015 Accepted: November 25, 2015 Published: December 04, 2015
Although pluripotent stem cell (PSC) therapy has advantages for clinical applications because of the self-renewal and multi-lineage differentiation abilities of PSCs, it also has disadvantages in terms of the potential for PSCs to undergo malignant transformation or unexpected differentiation. The prevention of teratoma formation is the largest hurdle of all. Despite intensive studies that have investigated ways to block teratomas, such methods have yet to be further developed for clinical use. Here, a new approach has focused on exerting anti-tumorigenic effects using a novel mica fine particle (MFP) designated STB-HO. Treatment with STB-HO regulated pluripotency- and apoptosis-related genes in differentiating human embryonic stem (hES) cells, while there is no effects in undifferentiated hES cells. In particular, STB-HO blocked the anti-apoptotic gene BIRC5 and activated p53, p21 and the pro-apoptotic proteins Bim, Puma and p-Bad during early spontaneous differentiation. Moreover, STB-HO-pretreated differentiating hES cells did not give rise to teratomas following in vivo stem cell transplantation. Our in vitro and in vivo results suggest a method for teratoma prevention in the context of PSC-derived cell transplantation. This novel MFP could break through the limitations of PSC therapy.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.